arrow
V

Val Gebski

University of Sydney
H指数:86
被引数:3.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A randomised clinical trial of a digital self-management package for people with interstitial lung disease: the REBUILD-SM protocol

一项针对间质性肺疾病患者数字自我管理方案的随机对照试验:REBUILD-SM方案

2025-12-050
OAAI
Sertraline to reduce recidivism in impulsive violent offenders (ReINVEST): a randomised double blind clinical trial

舍曲林减少冲动性暴力罪犯再犯率(ReINVEST):一项随机双盲临床试验

2025-11-270
OAAI
Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial

循环肿瘤DNA指导的辅助治疗在局部晚期结肠癌中的应用:随机II/III期DYNAMIC-III试验

2025-10-200
PRE
Erratum to ‘Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma’ [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101644]

勘误:‘Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma’ [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101644]

2025-06-110
PRE
Impact of gated FDG PET/CT on the staging of patients with suspected or proven newly diagnosed advanced epithelial ovarian, fallopian tube, and primary peritoneal cancer: results from a non-randomized, phase II clinical trial

门控FDG PET/CT对可疑或确诊的新诊断晚期上皮性卵巢癌、输卵管癌和原发性腹膜癌患者分期的影响:一项非随机、II期临床试验的结果

2025-04-190
PRE
The TROG 15.01 stereotactic prostate adaptive radiotherapy utilizing kilovoltage intrafraction monitoring (SPARK) clinical trial database
2024-11-230
OA
Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study

术前乳腺MRI后选择性早期乳腺癌患者的术后放疗遗漏 (展望): 一项前瞻性两臂研究的主要结果

LANCET
IF88.5
2024-01-0121
PRE
Proton versus photon therapy for esophageal cancer - A trimodality strategy (PROTECT) NCT050555648: A multicenter international randomized phase III study of neoadjuvant proton versus photon chemoradiotherapy in locally advanced esophageal cancer
2024-01-014
OAAI
Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy
2023-05-319
OAAI
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)

INTEGRATE II: 包含regorafenib的方案与难治性晚期胃食道癌 (AGOC) 的护理标准的随机III期对照试验: 澳大利亚胃肠道试验组 (AGITG) 的一项研究

2023-02-227
OAAI
Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial

食管鳞状细胞癌的新辅助放化疗和手术与根据需要进行挽救性手术的确定性放化疗的比较: 随机对照NEEDS试验的研究方案

2022-07-1320
OAAI
A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: study protocol

局部直肠癌放化疗后完全临床反应者观察和等待的纵向队列研究: 研究方案

2022-03-014
OAAI
Patient-Reported Bowel, Urinary, and Sexual Outcomes After Laparoscopic-Assisted Resection or Open Resection for Rectal Cancer The Australasian Laparoscopic Cancer of the Rectum Randomized Clinical Trial (ALaCart)

腹腔镜辅助直肠癌切除术或开腹直肠癌切除术后患者报告的肠,尿和性结局澳大利亚腹腔镜直肠癌随机临床试验 (ALaCart)

2022-02-159
PRE
VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer

Vegf-a,VEGFR1和VEGFR2单核苷酸多态性与卡培他滨,贝伐单抗和丝裂霉素c治疗转移性结直肠癌的AGITG MAX试验的结果

2022-01-2413
OAAI